Can antibodies flush out hidden HIV? new trial aims to find out
NCT ID NCT05612178
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether two lab-made antibodies, 3BNC117-LS and 10-1074-LS, can safely reduce the hidden HIV reservoir in people already on suppressive antiretroviral therapy (ART). The trial involves 105 adults with HIV who will receive three infusions of the antibodies or a placebo over 40 weeks. Researchers will monitor side effects and measure changes in the number of HIV-infected cells to see if the antibodies can help control the virus long-term.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 3BNC117-LS and 10-1074-LS (antibodies)
- What this could lead to
- If successful, this could point toward a way to shrink the hidden HIV reservoir, potentially allowing people with HIV to control the virus without daily medication.
- What could go wrong
- This is an early phase 1 trial focused on safety, so it may not show a meaningful reduction in the reservoir. The antibodies are given alongside standard ART, and any benefit is uncertain at this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
The Rockefeller University
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for Drug-Resistant HIV: early access to TMC125
- Cancer drug venetoclax takes aim at HIV's secret hiding spots
- Engineered immune cells aim to keep HIV in check without daily pills
- Can antibodies shield newborns from HIV? early trial begins
- Experimental HIV vaccine trial aims to boost immunity in people on suppressive therapy
- Could a Two-Drug HIV pill work for transgender women?